Drug Treatments for Fatty Liver Disease Linked to Metabolism in People with Type 2 Diabetes

Metformin is commonly used as the first-line agent for the management of hyperglycemia in individuals with T2D. Through its insulin-sensitizing effects, metformin typically reduces HbA1c by approximately 1% and leads to a modest weight reduction [15, 16], while having a neutral effect on major adverse cardiovascular outcomes [2]. Metformin does not provide any meaningful histological improvement in MASLD and should not be used for this purpose [1, 2, 17]. Although observational studies have suggested reduced mortality and a lower incidence of hepatocellular carcinoma (HCC) among people with T2D and MASH-related bridging fibrosis or compensated cirrhosis [18], a recent meta-analysis that accounted for statin and aspirin use did not demonstrate a clear protective effect of metformin on HCC incidence [19].

Dipeptidyl peptidase-4 inhibitors (DPP4is) are commonly used on top of metformin for the management of hyperglycemia especially in cases of severe renal impairment. Owing to their low risk of hypoglycemia, DPP4is are also suitable for frail individuals in whom a less stringent glycemic target is appropriate. By enhancing the action of endogenous incretin hormones, DPP4is lower HbA1c by approximately 0.6% [15]. They do not promote weight loss and have not demonstrated benefit on major adverse cardiovascular outcomes [2, 16]. Histological data regarding the efficacy of DPP4is in people with MASLD are limited [2]. In a small randomized controlled trial (RCT), 12 participants with T2D and histologically confirmed MASH were allocated to either sitagliptin 100 mg/day or placebo [20]. After 24 weeks, sitagliptin did not improve liver fibrosis or MASH activity. In another RCT, 50 participants with MASLD and either prediabetes or T2D were allocated to sitagliptin 100 mg/day or placebo for 24 weeks [21]. In this case, MASLD was defined based on magnetic resonance imaging proton density fat fraction (MRI-PDFF) and fibrosis was assessed with magnetic resonance elastography. At study completion, no significant differences were observed between treatment groups in either MRI-PDFF or MRE. As such, DPP4is should not be considered for the management of MASLD in people with T2D [2, 22]. With the exception of vildagliptin, this drug class can be used in patients with cirrhosis and moderately impaired liver function, but are not recommended in cases of severe hepatic impairment [23].

Despite their ability to lower HbA1c by roughly 1%, the use of sulphonylureas in people with T2D has progressively declined mainly due to their increased risk of hypoglycemia and the absence of renal, cardiovascular, or weight-reduction benefits compared with existing medications [15]. To date, there are no RCTs with histological endpoints assessing the efficacy of this drug class in MASLD [22, 24]. Results of RCTs in people with T2D and MASLD have reported minor benefits in liver steatosis based on noninvasive indices [25]. Given the increased risk of hypoglycemia related to sulphonylureas use especially in individuals with cirrhosis and impaired liver function, and the lack of evidence on histological endpoints sulphonylureas should not be considered for the management of MASLD [1, 23].

Insulin initiation should be considered regardless of background treatment in people with markedly elevated HbA1c levels or severe hyperglycemia [14]. Moreover, insulin is the preferred pharmacologic option for managing hyperglycemia in decompensated cirrhosis [26]. Despite its propensity to cause weight gain, the increased risk of hypoglycemia, and its neutral effect on cardiovascular and renal outcomes [2], results from RCTs in participants with MASLD and T2D have reported a beneficial effect on liver steatosis as assessed by means of MRI-PDFF with a relative reduction from baseline ranging from 5% to 11% [27, 28]. Whether these improvements in steatosis translate into favourable effects on MASH activity or fibrosis remains unclear [29]. Consequently, insulin should not be used for the treatment of MASLD in people with T2D. Nevertheless, clinicians should remain aware of its antisteatotic effect despite its weight-promoting properties.

Pioglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist that enhances insulin sensitivity and promotes triglyceride storage in adipose tissue, thereby reducing ectopic lipid deposition in the liver [22, 29]. In the first RCT, 55 individuals with prediabetes or T2D and histological confirmed MASH were allocated to pioglitazone 45 mg/daily or placebo on top of a hypocaloric diet [30]. After six months of treatment, pioglitazone significantly improved all components of NAS score [steatosis (65% vs. 38%, p = 0.03), ballooning (54% vs. 24%, p = 0.02), and lobular inflammation (65% vs. 29%, p = 0.008)] compared with placebo, although changes in fibrosis did not differ significantly between groups (46% vs. 33%, p = 0.08). In another study of longer duration (18 months), 101 participants with prediabetes or T2D and histological confirmed MASH were randomly allocated to either pioglitazone 45 mg/daily or placebo [31]. Pioglitazone resulted in a greater proportion of participants achieving a ≥ 2-point reduction in NAS without worsening of fibrosis (58% vs. 17%, p < 0.001) and a higher rate of MASH resolution (51% vs. 19%, p < 0.001). However, there was no significant difference in the proportion of patients achieving ≥ 1-point improvement in fibrosis between groups (20% vs. 13%, p = 0.13). More recently, an RCT with paired biopsy data randomized 105 individuals with T2D and MASH in a 1:1:1 ratio to placebo, vitamin E, or combination therapy with vitamin E plus pioglitazone 45 mg/daily [32]. Combination therapy significantly increased the proportion of participants achieving a ≥ 2-point reduction in NAS without worsening of fibrosis (54% vs. 19%, p = 0.003), whereas vitamin E alone did not (31% vs. 19%, p = 0.26). Neither active treatments showed a clear fibrosis benefit. The beneficial effect of pioglitazone on MASH resolution appears consistent in RCTs involving people without diabetes as well [33–35]. Across trials, improvements in fibrosis have been modest, with placebo-subtracted fibrosis response rates typically ranging from 9% to 22% [2]. It is important to note that most studies were underpowered for fibrosis endpoints. Meta-analyses confirm the beneficial effect of pioglitazone on MASH resolution, while also providing evidence for fibrosis improvement [36, 37]. As a result, pioglitazone should be considered for the management of MASH in people with T2D. Nevertheless, it should be noted that its primary benefit lies in improving hepatic inflammation, while evidence supporting its antifibrotic effects is comparatively weaker. Moreover, the use of pioglitazone requires careful consideration due to concerns about fluid retention and potential worsening of heart failure, as well as its limited applicability in individuals with decompensated cirrhosis [14, 23].

Since their introduction, GLP-1 RAs have emerged as a leading drug class for the management of T2D. This is driven by their robust glucose-lowering efficacy [15, 38], clinically meaningful weight loss [38], and demonstrated protective effects against major adverse cardiovascular and renal events [39].

Among the various GLP-1 receptor agonists, liraglutide was the first to demonstrate therapeutic potential in the management of MASH. In a small phase 2 trial, 52 individuals with biopsy-confirmed MASH (33% with T2D) were randomized to liraglutide 1.8 mg/daily or placebo for 48 weeks [40]. Treatment with liraglutide resulted in MASH resolution in 39% of participants compared with 9% in the placebo group (relative risk 4.3, 95% CI 1.0–17.7). Furthermore, participants in the liraglutide group experienced a lower rate of fibrosis progression compared with placebo.

Semaglutide is the GLP-1 RA with the largest amount of data on MASH histological endpoints. In a phase 2 RCTs of paired histological data, 320 patients with non-cirrhotic MASH (62% with T2D) were allocated to semaglutide 0.1 mg/daily or 0.2 mg/daily or 0.4 mg/daily or placebo for 72 weeks [41]. At the end of treatment, MASH resolution without worsening of fibrosis was achieved in 40% of participants in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P < 0.001 for semaglutide 0.4 mg vs. placebo). Fibrosis improvement without worsening of MASH occurred in 43% of participants in the 0.4-mg group and in 33% in the placebo group (P = 0.48). Results were similar in subgroup analyses based on diabetes status. Recently, the FDA approved semaglutide 2.4 mg/weekly for the management of non-cirrhotic MASH following the results of a pre-planned interim analysis of the phase 3 ESSENCE trial [42]. In this study 800 participants (56% with T2D) were randomly allocated to either semaglutide 2.4 mg/weekly or placebo. After 72 weeks, 62.9% of the 534 participants in the semaglutide group achieved resolution of MASH without worsening of fibrosis compared with 34.3% of the 266 patients in the placebo group (estimated difference, 28.7%, 95% CI, 21.1 to 36.2; p < 0.001). Similarly, fibrosis improvement without worsening of MASH was reported in 36.8% in the semaglutide group and in 22.4% in the placebo group (estimated difference, 14.4%, 95% CI, 7.5 to 21.3; p < 0.001) [43]. Of note, the mean change form baseline in body weight was considerably greater in the semaglutide group compared with placebo. Nevertheless, mediation analyses suggest that both weight loss–dependent and weight loss–independent metabolic mechanisms contribute to semaglutide-induced improvements in histological endpoints [44]. Similarly, post hoc subgroup analyses demonstrated that the proportion of participants achieving either MASH resolution or fibrosis improvement was consistently higher with semaglutide than with placebo, irrespective of glycemic status [45]. A phase 2 RCT with paired histological assessments evaluated the efficacy of semaglutide in 71 patients with MASH-related compensated cirrhosis (75% with T2D) [46]. After 48 weeks, there was no difference between semaglutide 2.4 mg/weekly and placebo in fibrosis improvement (odds ratio 0.28, 95% CI 0.06–1.24; p = 0.087). Nonetheless, the overall incidence of adverse events was similar between groups (89% vs. 79%), and no worsening of hepatic function or decompensating events attributable to semaglutide were observed. More recently, the results of the SAMARA trial have demonstrated that non-invasive tests can reliably identify patients with at-risk MASH who are eligible for treatment with semaglutide and can also be used to monitor therapeutic response, obviating the need for liver biopsy assessment [47].

Histological data for other GLP-1 receptor agonists are currently lacking. However, evidence indicates that dulaglutide 1.5 mg weekly and exenatide 10 mcg twice daily can reduce liver steatosis by approximately 32% and 41%, respectively, as assessed by MRI-PDFF in people with T2D and MASLD [48, 49]. This is clinically relevant, as a ≥ 30% relative reduction in MRI-PDFF is associated with higher odds of histological improvement and MASH resolution [50].

Consequently, among available GLP-1 RAs, semaglutide and liraglutide have proven efficacy in MASH resolution. To date, only semaglutide has shown a favorable effect on fibrosis however, this antifibrotic benefit appears to occur only at the obesity-approved dose of 2.4 mg weekly. Other GLP-1 RAs, such as dulaglutide, may also lead to MASH resolution, although this conclusion is inferred indirectly from non-invasive assessments.

Tirzepatide is a novel dual GIP/GLP-1 RA approved for the management of T2D and obesity. Meta-analyses demonstrate its superiority over semaglutide with respect to both HbA1c reduction and weight loss [51]. Furthermore, recently published data indicate that tirzepatide is noninferior to dulaglutide for the composite endpoint of cardiovascular death, myocardial infarction, or stroke in individuals with T2D and established atherosclerotic cardiovascular disease [52].

In an MRI-PDFF substudy of the SURPASS-3 trial, tirzepatide 10 mg and 15 mg achieved reductions in liver fat content of 47% and 39%, respectively, compared with insulin degludec in individuals with T2D [28]. Further insights come from a phase 2 RCT with paired liver histology, in which 190 individuals with non-cirrhotic MASH (58% with T2D) were randomized to tirzepatide 5 mg/weekly, 10 mg/weekly, or 15 mg/weekly, or placebo, for 52 weeks [53]. At study end, MASH resolution without worsening of fibrosis occurred in 10% of participants receiving placebo, compared with 44%, 56%, and 62% in the 5-mg, 10-mg, and 15-mg tirzepatide groups, respectively (p < 0.001 for all tirzepatide doses vs. placebo). Fibrosis improvement without worsening of MASH was achieved in 30% of the placebo group, versus 55% with tirzepatide 5 mg (estimated difference 25%; 95% CI, 5–46), 51% with tirzepatide 10 mg (estimated difference 22%; 95% CI, 1–42), and 51% with tirzepatide 15 mg (estimated difference 21%; 95% CI, 1–42). Results from participant level exploratory analyses for the same trial suggest that in the T2D subgroup, participants who achieved either MASH resolution or fibrosis improvement (responders) had greater weight and HBA1c reduction compared to non-responders. Similar to semaglutide, mediation analyses revealed that both weight loss–dependent and weight loss–independent mechanisms contribute to tirzepatide-induced improvements in histological endpoints [54].

As a result, tirzepatide should be considered for the management of MASH in people with T2D. Nevertheless, its primary benefit appears to be the improvement of hepatic inflammation, while evidence supporting antifibrotic effects is comparatively weaker. These estimates derive from a single RCT and require confirmation in future trials of longer duration.

SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, thereby increasing urinary glucose excretion [22]. In addition to their moderate-to-high glucose-lowering efficacy, these agents confer substantial cardiovascular and renal benefits in individuals with T2D [55], while also promoting weight loss [16].

Evidence for the efficacy of SGLT2 inhibitors in individuals with MASLD and T2D largely derives from RCTs using non-invasive biomarkers, mainly MRI-PDFF [56]. Across these studies, SGLT2 inhibitors have consistently demonstrated improvements in hepatic steatosis, with reductions in MRI-PDFF ranging from 10% to 31%, with empagliflozin generally producing the largest effects. More recently, an RCT evaluated dapagliflozin 10 mg/daily in individuals with MASH using paired histological data [57]. After 48 weeks of treatment, MASH resolution without worsening of fibrosis occurred in 23% of participants receiving dapagliflozin versus 8% in the placebo group (p = 0.01). Similarly, fibrosis improvement without worsening of MASH was observed in 45% of the dapagliflozin group compared with 20% of the placebo group (p = 0.001).

Overall, SGLT2 inhibitors are able to improve steatosis while, indirect evidence form noninvasive indices suggest their potential to improve steatohepatitis. To date, only dapagliflozin has demonstrated favourable effects on both hepatic inflammation and fibrosis histologically however, these findings require further confirmation in future trials. Evidence regarding the effect of this drug class in individuals with cirrhosis remains limited. In a population-based cohort study, SGLT2 inhibitors were associated with a lower risk of hepatic decompensation compared with thiazolidinediones, while being comparable to GLP-1 RAs [58]. Figure 1 summarizes the existing evidence on the effect of all the approved glucose-lowering drugs on weight, renal and cardiovascular outcomes as well as MASLD-related outcomes.

As of December 2025, the FDA had approved semaglutide 2.4 mg/weekly and resmetirom -a thyroid hormone receptor-β (THR-β) agonist- 80/100 mg daily for the management of non-cirrhotic MASH. EMA has also approved resmetirom for the same indication. The evidence of semaglutide effectiveness in MASLD is presented in the previous section of this review.

Resmetirom’s regulatory approval was based on the positive results of the phase 3 MAESTRO-NASH trial [59]. In this study, 966 participants with non-cirrhotic MASH (67% with T2D) were randomized to receive oral resmetirom 80 mg/daily, 100 mg/daily, or placebo. After 52 weeks of treatment, both resmetirom doses achieved higher rates of MASH resolution without worsening of fibrosis—25.9% with 80 mg and 29.9% with 100 mg—compared with 9.7% in the placebo group. Similarly, fibrosis improvement without worsening of MASH occurred more frequently with resmetirom (24.2% and 25.9% with the two doses) than with placebo (14.2%). These findings were consistent in subgroup analyses of participants with T2D. Notably, resmetirom therapy produced significant reductions in low-density lipoprotein cholesterol of up to 16%, with no apparent effect on body weight.

Given that cardiovascular mortality constitutes the leading cause of death in individuals with MASH, the cardiovascular profile of approved therapies is of critical clinical importance. However, there remains a paucity of evidence regarding the effect of resmetirom on cardiovascular outcomes, as dedicated trials have not yet been conducted. In contrast, semaglutide is supported by large, well-conducted cardiovascular outcomes trials demonstrating significant cardiovascular benefits in individuals with T2D, as well as in people with overweight or obesity without diabetes.

Despite several unsuccessful candidates in previous years, many agents have already shown promising results in phase 2 trials of histological endpoints and are currently investigated in phase 3 trials. The evidence for these drugs is presented below with an emphasis on their possible effect on T2D. They target either metabolism or liver-specific pathways of hepatocyte injury, including fatty acid uptake, de novo lipogenesis, triglyceride formation, oxidative stress, inflammation and cell death [60]. In addition, glucose-lowering medications (Table 1) and other emerging agents with distinct mechanisms of action (Table 2) are under investigation for the management of MASH, either as monotherapy or in combination regimens.

Survodutide is a novel dual glucagon/GLP-1 RA administered subcutaneously. In a phase 2 RCT, 293 participants with non-cirrhotic MASH (39% with T2D) were assigned to three different weekly doses of survodutide (2.4 mg, 4.8 mg, or 6.0 mg) or placebo [61]. After 48 weeks of treatment, survodutide achieved higher rates of MASH improvement without worsening of fibrosis (47%, 62%, and 43% in the 2.4 mg, 4.8 mg, and 6.0 mg groups, respectively compared with 22% in the placebo group). Fibrosis improvement rates were numerically higher with survodutide (34%, 36%, and 34% across the three doses) versus placebo (22%). Subgroup analyses based on diabetes status are not currently available. However, in a recently published placebo- and active-controlled trial in individuals with T2D, survodutide produced greater reductions in HbA1c and body weight compared with both placebo and semaglutide 1 mg [62]. Notably, high-dose survodutide led to ≥ 5% weight loss in more than 50% of participants and ≥ 10% weight loss in more than 25% [62]. Survodutide will be further evaluated in the phase 3 LIVERAGE trial (NCT06632444↗), which will enroll participants with MASH and F2–F3 fibrosis. Mazdutide, another once-weekly dual glucagon/GLP-1 receptor agonist, achieved resolution of steatosis in more than 70% of participants in a recently announced 48-week analysis of a clinical trial conducted in individuals with obesity [63]. This agent has also shown promising glucose-lowering effects in individuals with T2D, achieving greater reductions in HbA1c compared with semaglutide (-2.03% vs. -1.84%) [64]. In a recent phase 2 RCT of pemvidutide, MASH resolution without worsening of fibrosis was noted in 58% and 52% (two different dose regiments) compared to 20% in the placebo group at 24 weeks with no significant difference in fibrosis improvement without worsening of MASH [63]. Retatrutide is a first-in-class, once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors. In a phase 2 RCT including 281 participants with T2D, retatrutide administered at 12 mg once-weekly, achieved superior reduction in HbA1c (up to 2.02%) at 24 weeks, significantly outperforming placebo and active comparator dulaglutide (1.41%) [65]. In another placebo-controlled phase 2 trial of obese, non-diabetic participants retatrutide achieved a mean weight loss of 24.2% at 48 weeks [66]. A prespecified substudy of this obesity trial assessed hepatic outcomes in participants with MASLD and baseline liver fat content ≥ 10% measured by MRI-PDFF [67]. By week 48, participants receiving the highest doses (8 mg and 12 mg) achieved a mean relative liver fat reduction of 81–86%. Resolution of steatosis, defined as liver fat content < 5%, was observed in more than 90% of participants treated with the 12 mg dose. A dedicated phase 3 RCT evaluating the cardiovascular safety and efficacy of retatrutide is currently ongoing (NCT06383390↗), with the aim of assessing its impact on major adverse cardiovascular outcomes. In parallel, the phase 3 SYNERGY-OUTCOMES trial (NCT07165028↗) is actively recruiting individuals with high-risk MASLD, identified using noninvasive indices. This large-scale study plans to enroll approximately 4,500 participants and is designed to compare retatrutide, tirzepatide, and placebo with respect to major adverse liver outcomes. Lastly, in the ongoing DD01-DN-02 (NCT06410924↗) phase 2 study, DD01, another once-weekly dual glucagon/GLP-1 RA met the primary endpoint at week 12 in reducing liver fat by more than 30% in 75.8% of participants in the intervention group (compared to 11.8% in the placebo group) with liver fat normalization observed in 48.5% [63].

Fibroblast growth factor 21 (FGF21) is a peptide hormone secreted primarily by the liver and, to a lesser extent, by adipose tissue, exerting a broad range of metabolic effects [68, 69]. Efruxifermin, a subcutaneous, long-acting IgG Fc-FGF21 fusion protein, pegozafermin, a subcutaneous, long-acting glycopegylated recombinant FGF21 analogue and efimosfermin alpha, a very long-acting IgG1 Fc-conjugated analogue, are currently studied in phase 3 trials after successful phase 2 results [70].

A phase 2b RCT of 128 participants with biopsy-confirmed MASH with F2 or F3 fibrosis compared two different weekly subcutaneous doses of efruxifermin (28 mg or 50 mg) with placebo [71]. After 96 weeks of treatment, only high dose efruxifermin resulted in significantly higher rates of fibrosis improvement without worsening of MASH compared with placebo (estimated difference 31%; 95% CI, 12 to 42; p = 0.003). This favorable effect on fibrosis was more pronounced in individual with T2D and F3 fibrosis. Both efruxifermin doses resulted in higher rates of MASH resolution without worsening of fibrosis—37% to 40%—versus 19% in the placebo group. Although efruxifermin had no major effect on glycemic control (HbA1c increase of 0.2% for efruxifermin 50 mg), there were favorable effects on insulin resistance and lipid profile. In addition, results from a phase 2 trial in individuals with T2D and F1–F3 MASH, which evaluated efruxifermin as an add-on to stable GLP-1 RA therapy, suggest that efruxifermin may serve as a safe adjunctive option to enhance MASLD management in people with diabetes on background antihyperglycemic medication [72]. Efruxifermin is currently being investigated in the phase 3 SYNCHRONY Histology trial (NCT06215716↗), enrolling participants with MASH and F2–F3 fibrosis.

In a 24-week, phase 2b RCT of 222 individuals with biopsy-proven MASH and F2–F3 fibrosis, pegozafermin administered in three subcutaneous dosing regimens (15 mg and 30 mg once weekly, and 44 mg once every two weeks) was compared with placebo [73]. Both the 30 mg dose (difference vs. placebo 19%; 95% CI, 5–32; p = 0.009) and the 44 mg dose (difference vs. placebo 20%; 95% CI, 5–35; p = 0.0018) resulted in higher rates of fibrosis improvement without worsening of MASH compared with placebo. In participants with T2D, only the 44 mg regimen retained its antifibrotic effect. All pegozafermin doses produced higher rates of MASH resolution without worsening of fibrosis (37% with 15 mg, 23% with 30 mg, and 26% with 44 mg compared with 2% in the placebo group). In participants with T2D, this effect was retained only with the 30 mg and 44 mg dosing regimens. Although pegozafermin had no meaningful effect on HbA1c (reductions of up to 0.3%) and body weight (reductions of up to 1.2 kg), results suggest a favourable effect on triglyceride levels. The two higher-dose regimens are now being investigated in the phase 3 ENLIGHTEN-fibrosis trial (NCT06318169↗) in people with MASH and F2–F3 fibrosis.

Efimosfermin alfa is a long-acting FGF21 analogue that, unlike previous agents in this drug class, is administered once monthly. In a 24-week phase 2 trial, monthly efimosfermin 300 mg resulted in higher rates of MASH resolution without worsening of fibrosis, and higher rates of fibrosis improvement without worsening of MASH (68% and 45%, respectively) compared with placebo (29% and 21%, respectively) [74, 75]. The phase 3 ZENITH-1 trial (NCT07221227↗) is currently ongoing, recruiting participants with MASH and F2–F3 fibrosis.

Lanifibranor is an orally administered pan-PPAR agonist. In a 24-week, phase 2b RCT, 247 participants with non-cirrhotic MASH (42% with T2D) were allocated to lanifibranor 800 mg/daily, 1200 mg/daily, or placebo [76]. At the end of treatment, both lanifibranor doses achieved higher rates of MASH resolution without worsening of fibrosis (39% with 800 mg and 49% with 1200 mg) compared with placebo (22%). In addition, the 1200-mg dose led to fibrosis improvement without worsening of MASH in 48% of participants, versus 22% in the placebo arm. In participants with MASH and T2D, lanifibranor 1200 mg was superior to placebo for both histological endpoints, with MASH resolution without fibrosis worsening occurring in 45.4% versus 19.5%, and fibrosis improvement without MASH worsening in 51.3% versus 28.8%. Notably, lanifibranor resulted in significant improvements in insulin resistance, with favourable effects on glycemic parameters and lipid profile, despite its associated weight-gaining effects [76, 77]. Lanifibranor is currently under investigation in the ongoing phase 3 NATIV3 trial (NCT04849728↗), enrolling individuals with biopsy-proven MASH and F2–F3 fibrosis.

ION224 is a novel antisense oligonucleotide DGAT-2 inhibitor, that suppresses de novo lipogenesis. In a recently published phase 2 RCT of 160 participants with MASH (51% with T2D), once-monthly subcutaneous administration of ION224 at doses of 90 mg and 120 mg resulted in significantly higher rates of a ≥ 2-point reduction in NAS and histological resolution of MASH compared with placebo [78].

This article does not contain any studies with human or animal subjects performed by any of the authors.